Cargando…

The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells

The non-canonical Wnt signalling receptor ROR1 is aberrantly expressed in numerous cancers, including ovarian and endometrial cancer. We previously reported that silencing ROR1 could inhibit the proliferation and metastatic potential of ovarian and endometrial cancer cells in vitro. Zilovertamab is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Dongli, Kaufmann, Gunnar F., Breitmeyer, James B., Dickson, Kristie-Ann, Marsh, Deborah J., Ford, Caroline E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033071/ https://www.ncbi.nlm.nih.gov/pubmed/35456672 http://dx.doi.org/10.3390/pharmaceutics14040837

Ejemplares similares

P1435: PRECLINICAL EVALUATION OF ZILOVERTAMAB-BASED ANTI-ROR1 CHIMERIC ANTIGEN RECEPTORS IN NK AND T CELLS
por: Meinke, S., et al.
Publicado: (2022)

ROR2 Is Epigenetically Regulated in Endometrial Cancer
por: Liu, Dongli, et al.
Publicado: (2021)

ROR1 and ROR2 expression in pancreatic cancer
por: Liu, Dongli, et al.
Publicado: (2021)

ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target
por: Liu, Dongli, et al.
Publicado: (2020)

P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE
por: Wang, M., et al.
Publicado: (2022)

Author Correction: ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target
por: Liu, Dongli, et al.
Publicado: (2022)

Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis
por: Henry, Claire, et al.
Publicado: (2017)

Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells
por: Yin, Zhengna, et al.
Publicado: (2017)

P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Yazji, S., et al.
Publicado: (2022)

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
por: Xie, Tao, et al.
Publicado: (2022)

Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
por: Henry, C E, et al.
Publicado: (2016)

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion
por: Henry, Claire, et al.
Publicado: (2015)

Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
por: Henry, C. E., et al.
Publicado: (2022)

Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2013)

Monoclonal Antibody Against ROR1 Induces Apoptosis in Human Bladder Carcinoma Cells
por: Bayat, Ali-Ahmad, et al.
Publicado: (2020)

Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1
por: John, Miya, et al.
Publicado: (2022)

Retraction: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells
Publicado: (2022)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer()
por: Henry, CE, et al.
Publicado: (2017)

Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine
por: Yee, Christine, et al.
Publicado: (2022)

Writing Histone Monoubiquitination in Human Malignancy—The Role of RING Finger E3 Ubiquitin Ligases
por: Marsh, Deborah J., et al.
Publicado: (2019)

The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells
por: Lee, Kyung-Jun, et al.
Publicado: (2023)

ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration
por: Ma, Sean S. Q., et al.
Publicado: (2016)

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies
por: Yang, Jiahui, et al.
Publicado: (2011)

Histone Monoubiquitination in Chromatin Remodelling: Focus on the Histone H2B Interactome and Cancer
por: Marsh, Deborah J., et al.
Publicado: (2020)

P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Ozcan, Muhit, et al.
Publicado: (2023)

Digoxin, an Overlooked Agonist of RORγ/RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)

Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
por: Hird, V., et al.
Publicado: (1993)

Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies
por: Osborn, Gabriel, et al.
Publicado: (2021)

P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY
por: Spurgeon, Stephen, et al.
Publicado: (2023)

MIR-379-5p Expression in Endometrial Cancer and Its Correlation with ROR1 Expression
por: Mosaada, Hala, et al.
Publicado: (2023)

A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models
por: Cortesi, Marilisa, et al.
Publicado: (2023)

RON, ROR1 and SUSD2 expression in tissues of endometrial carcinoma patients. Clinicopathological and prognostic implications
por: Abdelbary, Abeer M., et al.
Publicado: (2022)

ROR1 expression correlated with poor clinical outcome in human ovarian cancer
por: Zhang, Huilin, et al.
Publicado: (2014)

ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy
por: Rebagay, Guilly, et al.
Publicado: (2012)

Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies
por: Dave, Hema, et al.
Publicado: (2012)

Determination of crucial epitopes in the sperm protein calsperin employing synthetic peptides and monoclonal antibodies
por: Bergmann, Ann Christina, et al.
Publicado: (2022)

Human monoclonal antibodies and monoclonal antibody multispecificity.
por: Campbell, A. M., et al.
Publicado: (1987)

RORα and RORγ expression inversely correlates with human melanoma progression
por: Brożyna, Anna A., et al.
Publicado: (2016)

RORγt and RORα signature genes in human Th17 cells
por: Castro, Glenda, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j78oft98kei2ga3jmsrnh61ne0